ES2942297T3 - Formulaciones de polvo seco para inhalación - Google Patents

Formulaciones de polvo seco para inhalación Download PDF

Info

Publication number
ES2942297T3
ES2942297T3 ES15827152T ES15827152T ES2942297T3 ES 2942297 T3 ES2942297 T3 ES 2942297T3 ES 15827152 T ES15827152 T ES 15827152T ES 15827152 T ES15827152 T ES 15827152T ES 2942297 T3 ES2942297 T3 ES 2942297T3
Authority
ES
Spain
Prior art keywords
particles
acetylsalicylic acid
dry
less
dry powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15827152T
Other languages
English (en)
Spanish (es)
Inventor
Kambiz Yadidi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectura Inc
Original Assignee
Vectura Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55218356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2942297(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Inc filed Critical Vectura Inc
Application granted granted Critical
Publication of ES2942297T3 publication Critical patent/ES2942297T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES15827152T 2014-07-31 2015-07-31 Formulaciones de polvo seco para inhalación Active ES2942297T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462031811P 2014-07-31 2014-07-31
PCT/US2015/043128 WO2016019253A1 (en) 2014-07-31 2015-07-31 Dry powder formulations for inhalation

Publications (1)

Publication Number Publication Date
ES2942297T3 true ES2942297T3 (es) 2023-05-31

Family

ID=55218356

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15827152T Active ES2942297T3 (es) 2014-07-31 2015-07-31 Formulaciones de polvo seco para inhalación

Country Status (10)

Country Link
EP (2) EP3179986B1 (enExample)
JP (1) JP6850524B2 (enExample)
KR (2) KR102666667B1 (enExample)
CN (2) CN116687887A (enExample)
AU (2) AU2015296142A1 (enExample)
CA (1) CA2991760C (enExample)
DK (1) DK3179986T3 (enExample)
ES (1) ES2942297T3 (enExample)
PL (1) PL3179986T3 (enExample)
WO (1) WO2016019253A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176552A1 (en) 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
EP3463378A4 (en) 2016-06-03 2020-01-08 Otitopic Inc. DRY POWDER FORMULAS FOR INHALATION
AU2017432640B2 (en) * 2017-09-22 2023-11-30 Aspeya US Inc. Dry powder compositions with magnesium stearate
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
EP4311566A1 (en) 2022-07-28 2024-01-31 Vectura Inc. An inhaler comprising a retention element

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
HU219899B (hu) 1995-04-14 2001-09-28 Glaxo Wellcome Inc. Inhalálóberendezés flutikaszon-propionát adagolására mért dózisban
DE69634246T2 (de) 1995-04-14 2006-01-12 Nektar Therapeutics, San Carlos Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
EP1013269A4 (en) * 1997-06-06 2002-02-20 Shionogi & Co IMPROVEMENT OF A DRUG ADMINISTRATION SYSTEM
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
PL195212B1 (pl) 1997-09-29 2007-08-31 Nektar Therapeutics Preparat bioaktywny w postaci proszku i sposób jego wytwarzania
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
WO2000000215A1 (en) 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP2266549B1 (en) 2000-06-27 2019-08-07 Vectura Limited Method of making particles for use in a pharmaceutical composition
JP4368198B2 (ja) 2001-11-20 2009-11-18 アルカーメス，インコーポレイテッド 肺送達用の改良された粒状組成物
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
EP1556018A1 (en) * 2002-09-30 2005-07-27 Acusphere, Inc. Sustained release porous microparticles for inhalation
US20080044481A1 (en) * 2004-05-27 2008-02-21 Mordechai Harel Microparticles for Oral Delivery
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
JP2008534601A (ja) 2005-03-28 2008-08-28 ペリコー セラピューティクス， インコーポレイテッド 患者における副作用を予防または減少するための方法、組成物および処方物
KR20080016952A (ko) * 2005-06-13 2008-02-22 엘란 파마 인터내셔널 리미티드 나노입자형 클로피도그렐과 아스피린의 배합 제제
GB0621957D0 (en) * 2006-11-03 2006-12-13 Vectura Group Plc Inhaler devices and bespoke pharmaceutical compositions
WO2009026434A1 (en) 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
AU2009214443B2 (en) 2008-02-13 2013-10-10 Board Of Regents, The University Of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
CN104188909A (zh) 2009-04-24 2014-12-10 伊休蒂卡有限公司 用于制备商品化纳米颗粒和微粒粉末的方法
GB201102237D0 (en) * 2011-02-09 2011-03-23 Kuecept Ltd Particle formulation
US9216527B2 (en) 2012-02-09 2015-12-22 G & W Electric Company Solid-dielectric switch including a molded viewing window
CN104703584B (zh) 2012-02-28 2019-05-31 艾塞尤提卡控股公司 可吸入药物组合物
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
JP2016518388A (ja) * 2013-04-30 2016-06-23 オティトピック インク． 乾燥粉末配合および使用方法
PL3107548T3 (pl) * 2014-02-20 2022-10-31 Otitopic Inc. Suche formulacje w proszku do inhalacji

Also Published As

Publication number Publication date
EP4218734A1 (en) 2023-08-02
WO2016019253A1 (en) 2016-02-04
KR102603897B1 (ko) 2023-11-20
KR102666667B1 (ko) 2024-05-17
WO2016019253A9 (en) 2016-05-12
JP6850524B2 (ja) 2021-03-31
PL3179986T3 (pl) 2023-06-26
JP2017523189A (ja) 2017-08-17
CN107072947A (zh) 2017-08-18
KR20170039255A (ko) 2017-04-10
AU2015296142A1 (en) 2017-02-23
EP3179986B1 (en) 2023-03-15
AU2020203437A1 (en) 2020-06-11
EP3179986A1 (en) 2017-06-21
EP3179986A4 (en) 2018-02-07
CA2991760A1 (en) 2016-02-04
KR20230119032A (ko) 2023-08-14
CN116687887A (zh) 2023-09-05
CA2991760C (en) 2025-05-06
DK3179986T3 (da) 2023-05-01
AU2020203437B2 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
ES2922206T3 (es) Formulaciones de polvo seco para la inhalación
US11819569B2 (en) Treating inflammation with inhaled aspirin
AU2020203437B2 (en) Dry powder formulations for inhalation
US12343425B2 (en) Dry powder formulations for inhalation
US12144820B2 (en) Dry powder formulations for inhalation
HK1240081B (en) Dry powder formulations for inhalation
HK1240081A1 (en) Dry powder formulations for inhalation
HK1232442A1 (en) Dry powder formulations for inhalation
HK1232442B (en) Dry powder formulations for inhalation
HK40020066A (en) Dry powder formulations and methods of use